5-甲氧基酞嗪 | 1381770-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5-甲氧基酞嗪
• 英文名称: 5-methoxyphthalazine
• CAS: 1381770-02-0
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: YNVFYJQPIBCORQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-甲氧基酞嗪 在 scandium tris(trifluoromethanesulfonate) 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 26.0h， 生成 diethyl 4,4-dicyano-8-methoxy-3-phenyl-3,4-dihydro-1H-pyrido[2,1-a]phthalazine-1,1(2H,11bH)-dicarboxylate
  参考文献：
  名称：

  Sc(OTf)₃-Catalyzed [3 + 3] Cycloaddition of Cyclopropane 1,1-Diesters with Phthalazinium Dicyanomethanides

  摘要：

  The Sc(OTf)(3)-catalyzed diastereoselective [3 + 3] cycloaddition of phthalazinium dicyanomethanides with cyclopropane 1,1-diesters proceeded smoothly under mild reaction conditions, affording a variety of 3,4-dihydro-1H-pyrido[2,1-a]phthalazine derivatives in up to 99% yields with excellent diastereoselectivities.

  DOI：

  10.1021/acs.orglett.5b02003
• 作为产物：
  描述：

  3-甲氧基苯甲醛 在 正丁基锂 、 Lithium N-(N,N-dimethyl-2-aminoethyl)-N-methylamide 、 N,N-二甲基甲酰胺 、 氯化铵 、 一水合肼 作用下， 以 正己烷 、 四氢呋喃 、 水 为溶剂， 反应 18.67h， 生成 5-甲氧基酞嗪
  参考文献：
  名称：

  Sc(OTf)₃-Catalyzed [3 + 3] Cycloaddition of Cyclopropane 1,1-Diesters with Phthalazinium Dicyanomethanides

  摘要：

  The Sc(OTf)(3)-catalyzed diastereoselective [3 + 3] cycloaddition of phthalazinium dicyanomethanides with cyclopropane 1,1-diesters proceeded smoothly under mild reaction conditions, affording a variety of 3,4-dihydro-1H-pyrido[2,1-a]phthalazine derivatives in up to 99% yields with excellent diastereoselectivities.

  DOI：

  10.1021/acs.orglett.5b02003

文献信息

• Cu(I)-Catalyzed Highly Enantioselective [3 + 3] Cycloaddition between Two Different 1,3-Dipoles, Phthalazinium Dicyanomethanides and Iminoester-Derived Azomethine Ylides
  作者：Chunhao Yuan、Honglei Liu、Zhenzhen Gao、Leijie Zhou、Yalin Feng、Yumei Xiao、Hongchao Guo

  DOI：10.1021/ol503169d

  日期：2015.1.2

  The Cu(I)-catalyzed highly enantioselective [3 + 3] cycloaddition between two different 1,3-dipoles, phthalazinium dicyanomethanides and iminoester-derived azomethine ylides, has been achieved under mild reaction conditions, providing novel chiral heterocyclic compounds, 2,3,4,11b-tetrahydro-1H-pyrazino[2,1-a]phthalazine derivatives, in high yields with excellent diastereo- and enantioselectivies (up

  在温和的反应条件下，已实现了Cu（I）催化的两个不同的1,3-偶极，酞菁双氰胺和亚氨基酯衍生的偶氮甲碱的高对映选择性[3 + 3]环加成反应，提供了新颖的手性杂环化合物2,3 ，4,11b-四氢-1 H-吡嗪并[ 2,1- a ]酞嗪衍生物，高收率，具有出色的非对映和对映选择性（高达99％收率，99％ee，> 20：1 dr）。
• One-Pot Synthesis of Phthalazines and Pyridazino-aromatics: A Novel Strategy for Substituted Naphthalenes
  作者：Simon N. Kessler、Hermann A. Wegner

  DOI：10.1021/ol301167q

  日期：2012.7.6

  desired 1,2-diazine in good to excellent yields. The products have been applied to the bidentate Lewis acid catalyzed inverse electron-demand Diels–Alder (IEDDA) reaction opening a novel two-step entry into substituted naphthalenes, such as Naproxen.

  已经开发了一种新的一锅策略，从芳族醛开始合成酞嗪和哒嗪基-芳族化合物。容许从吸电子到供电子的各种取代基以良好或优异的产率提供所需的1,2-二嗪。该产品已应用于双齿路易斯酸催化的逆电子需求Diels–Alder（IEDDA）反应，开启了新型两步进入取代萘（如萘普生）的过程。
• INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS
  申请人：Disarm Therapeutics, Inc.

  公开号：US20220008405A1

  公开（公告）日：2022-01-13

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
• INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR
  申请人：Disarm Therapeutics, Inc.

  公开号：US20220072019A1

  公开（公告）日：2022-03-10

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.
• [EN] INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR<br/>[FR] INHIBITEURS DE SARM1 EN COMBINAISON AVEC NAD+ OU UN PRÉCURSEUR DE NAD+
  申请人：DISARM THERAPEUTICS INC

  公开号：WO2020081923A1

  公开（公告）日：2020-04-23

  The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.